OLON GROUP EXPANDS BIOPRODUCTION LEADERSHIP WITH KEY APPOINTMENTS IN FRANCE

KUALA LUMPUR, April 29 (Bernama) -- Olon Group, a global pharmaceutical contract development and manufacturing organisation (CDMO), has appointed Jérôme Bédier as chief executive officer (CEO) of its French entities and Andrea Conforto as marketing and sales vice president (VP) CDMO for Olon Biotech, the division dedicated to CDMO services for biologics.

According to a statement, the appointments were part of the group’s strategy to expand capabilities in antibody-drug conjugates (ADCs), highly potent active pharmaceutical ingredients (HPAPIs) and microbial bioproduction.

With the new leadership structure, Olon Group is accelerating the development of its fully integrated ADC offering, covering the entire value chain from cell line development to drug product manufacturing, including payload and linker production.

Olon Group VP of the biotech business unit, Maurizio Sartorato said strengthening leadership in bioproduction required a global and integrated vision.

"With Jérôme and Andrea, we are reinforcing our expertise to address the growing needs of the ADC, HPAPI and microbial bioproduction markets," he said.

Meanwhile, Bédier said he was thrilled to join Olon Group at a pivotal moment, highlighting the group's integrated capabilities in ADCs, HPAPIs and microbial bioproduction.

In addition, Conforto added that Olon was committed to providing biotech companies with comprehensive and flexible CDMO solutions while accelerating international expansion by leveraging the group’s excellence in bioproduction.

As CEO, Bédier will lead the integration of French CDMO capabilities within Olon Group and drive the expansion of its biopharmaceutical offering. He succeeds Alain Sainsot, who previously led GTP Bioways before its acquisition by Olon.

On the other hand, Conforto will focus on commercial strategy and global partnerships across Europe, North America, and Asia, working with biotech and pharma companies to bring complex therapies to market.

The group is also leveraging recent investments at its Rodano site in Italy, enhancing HPAPI production capabilities in line with its broader commitment to complex biopharmaceutical manufacturing. In parallel, Olon is reinforcing its microbial bioproduction capabilities, offering good manufacturing practice (GMP)-compliant clinical and commercial manufacturing for injectable biologics.

-- BERNAMA